purpose evaluate safety efficacy proton beam radiotherapy prt hepatocellular carcinoma patients methods eligibility criteria study solitary hepatocellular carcinoma hcc indication surgery local ablation therapy ascites age NUMBER years zubrod performance status NUMBER NUMBER comorbidities liver cirrhosis written informed consent prt administered doses NUMBER cobalt gray equivalent NUMBER fractions NUMBER weeks patients received transarterial chemoembolization local ablation combination prt results thirty patients enrolled NUMBER february NUMBER NUMBER male NUMBER female patients median age NUMBER years maximum tumor diameter ranged NUMBER NUMBER mm median NUMBER mm patients liver cirrhosis degree class NUMBER class b NUMBER patients acute reactions prt tolerated prt completed planned patients patients died hepatic insufficiency tumor recurrence NUMBER NUMBER months patients pretreatment indocyanine green retention rate NUMBER minutes NUMBER median period NUMBER months NUMBER NUMBER months patient experienced recurrence primary tumor actuarial local rate NUMBER NUMBER ci NUMBER NUMBER actuarial overall survival rate NUMBER years NUMBER NUMBER NUMBER conclusion prt showed excellent control primary tumor minimal acute toxicity study warranted scrutinize adequate patient selection order maximize survival benefit promising modality child pugh follow NUMBER year progression free